Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy and Cardiac Amyloidosis: From Clinical Management to Catheter Ablation Indication
Atrial fibrillation (AF) is the most common arrhythmia in patients affected by cardiomyopathies. Reports estimate a prevalence of 27% in patients with hypertrophic cardiomyopathy (HCM) and 40% in patients with cardiac amyloidosis (CA). The presence of AF typically results in progressive functional decline, an increased frequency of hospitalizations for heart failure, and a higher thromboembolic risk. Medical management using mainly beta-blockers or amiodarone has produced variable outcomes and a high rate of recurrence. Catheter ablation reduces symptom burden and complications despite a moderate rate of recurrence. Recent evidence suggests that an early rhythm control strategy may lead to more favorable short- and long-term outcomes. In this review, we summarize contemporary data on the management of AF in patients with cardiomyopathy (HCM and CA) with particular reference to the timing and outcomes of ablation procedures..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of Clinical Medicine - 13(2024), 2, p 501 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Raffaella Mistrulli [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Atrial fibrillation |
|---|
| doi: |
10.3390/jcm13020501 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ096179163 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ096179163 | ||
| 003 | DE-627 | ||
| 005 | 20240413143550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm13020501 |2 doi | |
| 035 | |a (DE-627)DOAJ096179163 | ||
| 035 | |a (DE-599)DOAJ04cd613728194acca42a20a84357bb78 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Raffaella Mistrulli |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy and Cardiac Amyloidosis: From Clinical Management to Catheter Ablation Indication |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Atrial fibrillation (AF) is the most common arrhythmia in patients affected by cardiomyopathies. Reports estimate a prevalence of 27% in patients with hypertrophic cardiomyopathy (HCM) and 40% in patients with cardiac amyloidosis (CA). The presence of AF typically results in progressive functional decline, an increased frequency of hospitalizations for heart failure, and a higher thromboembolic risk. Medical management using mainly beta-blockers or amiodarone has produced variable outcomes and a high rate of recurrence. Catheter ablation reduces symptom burden and complications despite a moderate rate of recurrence. Recent evidence suggests that an early rhythm control strategy may lead to more favorable short- and long-term outcomes. In this review, we summarize contemporary data on the management of AF in patients with cardiomyopathy (HCM and CA) with particular reference to the timing and outcomes of ablation procedures. | ||
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a hypertrophic cardiomyopathy | |
| 650 | 4 | |a cardiac amyloidosis | |
| 650 | 4 | |a catheter ablatio | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Armando Ferrera |e verfasserin |4 aut | |
| 700 | 0 | |a Melwyn Luis Muthukkattil |e verfasserin |4 aut | |
| 700 | 0 | |a Allegra Battistoni |e verfasserin |4 aut | |
| 700 | 0 | |a Giovanna Gallo |e verfasserin |4 aut | |
| 700 | 0 | |a Emanuele Barbato |e verfasserin |4 aut | |
| 700 | 0 | |a Francesco Raffaele Spera |e verfasserin |4 aut | |
| 700 | 0 | |a Damiano Magrì |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 13(2024), 2, p 501 |w (DE-627)DOAJ000006793 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:2, p 501 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm13020501 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/04cd613728194acca42a20a84357bb78 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/13/2/501 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 2, p 501 | ||